[Value of neuroleptic therapy in the self assessment of schizophrenic patients].
On the basis of clinical self-assessment scales (von Zerssen) and the Frankfurt questionnaire of complaints, it is demonstrated by the comparison of three groups of schizophrenic patients with one control group which is not undergoing therapy with neuroplegics that within the "genuine" groups the psychopathological factors investigated recede, sometimes quite significantly. Cross-over design treatment involving the control group has not revealed any significance. We conclude that when treating schizophrenic psychoses, psychosocial measures must accompany biological measures.
Klinik für Frauenpsychiatrie, Bezirkskrankenhauses für Neurologie und Psychiatrie Arnsdorf bei Dresden.
M
M
Heim
D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D003984:Dibenzazepines / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D012559:Schizophrenia / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D012565:Schizophrenic Psychology
D003984:Dibenzazepines; D003024:Clozapine; D006220:Haloperidol
Zum Stellenwert neuroleptischer Therapie in der Selbstbeurteilung schizophren Erkrankter.